125 related articles for article (PubMed ID: 27682966)
1. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review.
Raposo A; Tani C; Costa J; Mosca M
Acta Reumatol Port; 2016; 41(3):184-190. PubMed ID: 27682966
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis.
García-Carrasco M; Mendoza-Pinto C; Rojas-Villarraga A; Molano-González N; Vallejo-Ruiz V; Munguía-Realpozo P; Colombo AL; Cervera R
Autoimmun Rev; 2019 Feb; 18(2):184-191. PubMed ID: 30572140
[TBL] [Abstract][Full Text] [Related]
3. Clinical and epidemiological study of human papillomavirus infection in women with systemic lupus erythematosus in eastern brazilian amazon.
Amaral JL; Araújo MV; Dias GA; Ledebur EI; Quaresma JA; Fuzii HT
Acta Reumatol Port; 2017; 42(1):47-54. PubMed ID: 27750272
[TBL] [Abstract][Full Text] [Related]
4. [Human papillomavirus and systemic lupus erythematosus].
David E; Belot A; Lega JC; Durieu I; Rousset-Jablonski C
Rev Med Interne; 2021 Jul; 42(7):498-504. PubMed ID: 33485700
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus: often harmless but in some cases carcinogenic.
Prescrire Int; 2007 Jun; 16(89):115-9. PubMed ID: 17585425
[TBL] [Abstract][Full Text] [Related]
6. Screening of human papillomavirus infection in women with systemic sclerosis.
Martin M; Mougin C; Prétet JL; Gil H; Meaux-Ruault N; Puzenat E; Ramanah R; Aubin F; Touzé A; Coursaget P; Jacquin E; Magy-Bertrand N
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-145-8. PubMed ID: 25151849
[TBL] [Abstract][Full Text] [Related]
7. Incidence of neoplasms in the most prevalent autoimmune rheumatic diseases: a systematic review.
Machado RI; Braz Ade S; Freire EA
Rev Bras Reumatol; 2014; 54(2):131-9. PubMed ID: 24878860
[TBL] [Abstract][Full Text] [Related]
8. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
[TBL] [Abstract][Full Text] [Related]
10. Are women with lupus at higher risk of HPV infection?
Klumb EM; Pinto AC; Jesus GR; Araujo M; Jascone L; Gayer CR; Ribeiro FM; Albuquerque EM; Macedo JM
Lupus; 2010 Nov; 19(13):1485-91. PubMed ID: 20605875
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
13. An interleukin-10 gene polymorphism associated with the development of cervical lesions in women infected with Human Papillomavirus and using oral contraceptives.
Chagas BS; Gurgel AP; da Cruz HL; Amaral CM; Cardoso MV; Silva Neto Jda C; da Silva LA; de Albuquerque EM; Muniz MT; de Freitas AC
Infect Genet Evol; 2013 Oct; 19():32-7. PubMed ID: 23800422
[TBL] [Abstract][Full Text] [Related]
14. Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth.
Huang QT; Zhong M; Gao YF; Huang LP; Huang Q; Wang W; Wang ZJ; Yu YH
J Clin Virol; 2014 Nov; 61(3):321-8. PubMed ID: 25270088
[TBL] [Abstract][Full Text] [Related]
15. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer: screening and prevention.
Behtash N; Mehrdad N
Asian Pac J Cancer Prev; 2006; 7(4):683-6. PubMed ID: 17250453
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for cervical neoplasia in Denmark.
Kjaer SK
APMIS Suppl; 1998; 80():1-41. PubMed ID: 9693662
[TBL] [Abstract][Full Text] [Related]
18. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
20. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
